



PRESS RELEASE

The Hague, the Netherlands, September 14th, 2022



Appointment of Unilever veteran Marga Mathijssen as CEO of LiGalli

LiGalli BV, a Dutch based FemTech company, developer of a unique high-tech vaginal ring for a wide range of personalized therapies and diagnostics, announced today the retirement of Willem de Laat and appointment of Marga Mathijssen as CEO.

LiGalli BV is pleased to announce that Marga Mathijssen will become the CEO of LiGalli. She is the successor of Willem de Laat, the current CEO and founder, who will retire after 6 years and take a seat as a member of the Supervisory Board. It is anticipated that Marga will join the company as per October 1st, 2022. Marga will lead the company into the next phase by bringing the LiGalli MedRing to the market within the next 3 years.

Willem de Laat, gynecologist, and former Chief Medical Officer of Organon Biosciences: "After 6 years of hard work and providing all my knowledge and expertise, this is the ideal moment to step aside." In the 23 years working for Unilever, Marga has led many different businesses across the world. In the last 3 years she has established a significant and fast-growing Global Health and Wellbeing business for Unilever. The combination of her broad international business development and leadership experience and her passion for healthcare make her the ideal next CEO.

Marga Mathijssen: "Administering drugs has hardly changed in the last decades and there is a significant need for improvement. I am convinced that the LiGalli MedRing will change the way women are diagnosed, treated, and monitored. I am excited to be part of that big step forward."



Status of LiGalli's MedRing

The technical development of the MedRing has entered its last phase; making the final technical improvements, before kicking off the production. The connectivity of the LiGalli MedRing with a smartphone has recently been achieved, and the first generation of the app and web application are ready.

Further background about LiGalli's MedRing unique features


Vaginal rings and vaginal drug delivery enjoy a strongly increasing popularity, with over 150 clinical trials visible in a cross-sectional search in the ClinicalTrials.gov database and over 5000 available scientific publications on this topic.

All these vaginal rings currently are restricted to deliver a fixed dosage for a limited number of (gynecological) indications. These rings can neither be controlled via an app, nor confirm drug compliancy, nor collect data continuously for diagnostics.

In stark contrast with all existing vaginal rings, LiGalli develops a novel and uniquely different vaginal ring, the so-called LiGalli MedRing. The MedRing contains miniaturized high-tech components like a drug container, a pump, micro-electronics, and sensor(s). The connectivity with a smartphone enables scheduling of dosage and timing, and on demand drug administration as well as diagnostics. The LiGalli MedRing is discrete, elegant and convenient to use.

"The MedRing keeps amazing us by its possibilities and potential, even far beyond our wildest dreams", says Willem de Laat CEO.

LiGalli is founded in 2014 by Willem de Laat MD, PhD, former CMO of Organon Pharmaceuticals (part of AkzoNobel) and manager of the Dutch Top Institute Pharma.



For further information please visit www.ligalli.health or e-mail info@ligalli.health.